• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Wells Fargo reiterated coverage on Emergent BioSolutions with a new price target

    3/10/22 7:10:05 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $EBS alert in real time by email
    Wells Fargo reiterated coverage of Emergent BioSolutions with a rating of Equal-Weight and set a new price target of $40.00 from $37.00 previously
    Get the next $EBS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $EBS

    DatePrice TargetRatingAnalyst
    12/30/2024$15.00Buy
    H.C. Wainwright
    8/22/2024$16.00Buy
    Rodman & Renshaw
    3/7/2024$5.00Hold → Buy
    The Benchmark Company
    11/20/2023Underweight
    JP Morgan
    8/29/2023Buy → Hold
    The Benchmark Company
    4/10/2023$22.00Hold → Buy
    The Benchmark Company
    3/17/2023$23.00 → $9.00Neutral → Underweight
    JP Morgan
    11/10/2022Buy → Hold
    The Benchmark Company
    More analyst ratings

    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Emergent BioSolutions with a new price target

      H.C. Wainwright initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $15.00

      12/30/24 7:24:57 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Rodman & Renshaw initiated coverage on Emergent BioSolutions with a new price target

      Rodman & Renshaw initiated coverage of Emergent BioSolutions with a rating of Buy and set a new price target of $16.00

      8/22/24 7:22:39 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions upgraded by The Benchmark Company with a new price target

      The Benchmark Company upgraded Emergent BioSolutions from Hold to Buy and set a new price target of $5.00

      3/7/24 10:14:18 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    SEC Filings

    See more
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      5/23/25 4:06:03 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Emergent BioSolutions Inc.

      144 - Emergent BioSolutions Inc. (0001367644) (Subject)

      5/23/25 4:04:26 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Emergent BioSolutions Inc. (0001367644) (Filer)

      5/7/25 4:08:56 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Emergent BioSolutions Announces Addition to Russell 3000® Index

      GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the Company will be added to the broad-market Russell 3000® Index, effective after the U.S. market closes on June 27, 2025, as part of the annual reconstitution of the Russell U.S. stock indexes. "Inclusion in the Russell 3000® Index is an important milestone in Emergent's ongoing transformation," said Joe Papa, president and chief executive officer of Emergent BioSolutions. "This recognition reflects the positive momentum we are building across the organization and helps to position us to enter a new phase of disciplined, sustainable growth in the year ahead. It also reaffirms our c

      6/20/25 8:13:29 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies

      Continued commitment to reducing the number of opioid overdose deaths by expanding access, increasing awareness and educating the public about life-saving naloxone GAITHERSBURG, Md., June 05, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) is teaming up with Victoria's Voice Foundation to rally Americans to help save lives from the opioid epidemic on National Naloxone Awareness Day, which honors the late Victoria Siegel and others who have succumbed to overdose. As part of the effort, Victoria's Voice has launched the "Shine. Wear. Share. Care" campaign to raise awareness and provide educational resources to individuals, organizations and businesses that includes a purple

      6/5/25 7:00:21 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Emergent BioSolutions to Participate in Upcoming Investor Conferences

      GAITHERSBURG, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that members of its executive management team will participate in the following investor conferences: RBC Global Healthcare Conference (New York, New York)Fireside chat on Tuesday, May 20 at 3:35 pm ETVirtual attendees can participate via webcast Goldman Sachs Leveraged Finance Conference, May 29, 2025 (Dana Point, California) Benchmark's 5th Annual Healthcare House Call Virtual Investor ConferencePresentation on Thursday, May 29 Jefferies Global Healthcare Conference (New York, New York)Presentation on Thursday, June 5 at 1:25 pm ETVirtual attendees can participate via web

      5/14/25 7:32:11 AM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • EVP, Quality & Ethics, and CPL Glessner Coleen covered exercise/tax liability with 1,249 shares, decreasing direct ownership by 0.71% to 174,927 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:36 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Bioservices Hartzel William covered exercise/tax liability with 1,167 shares, decreasing direct ownership by 1% to 107,955 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:45 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Products Business Williams Paul Anthony covered exercise/tax liability with 464 shares, decreasing direct ownership by 0.54% to 85,871 units (SEC Form 4)

      4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

      6/10/25 4:12:27 PM ET
      $EBS
      Biotechnology: Pharmaceutical Preparations
      Health Care